Gossamer Bio (GOSS) News Today

Gossamer Bio, Inc. (NASDAQ:GOSS) is seeing a flurry of bullish analyst actions and market signals that may be underpinning today’s share strength.

• Positive Sentiment: Piper Sandler reiterated its Buy rating on Gossamer Bio, highlighting confidence in the company’s pipeline.Piper Sandler Reaffirms Buy
• Positive Sentiment: H.C. Wainwright maintained a Buy stance, pointing to promising prospects for Gossamer’s pulmonary arterial hypertension program.H.C. Wainwright Asserts Buy
• Positive Sentiment: Shares of Gossamer Bio gapped up on heavy volume, with analysts asking if now is the time to buy.Shares Gap Up – Time to Buy?
• Positive Sentiment: Unusually high options activity—2,867 calls traded versus a 1,169 average—suggests bullish positioning by traders.High Options Volume
• Positive Sentiment: MarketBeat reports a consensus Buy rating from four covering analysts, reinforcing bullish sentiment.Consensus Buy Rating
• Positive Sentiment: Traders bought a large volume of call options again, underlining continued speculative interest.Large Call Options Volume
• Positive Sentiment: Cantor reinforced its conviction in Gossamer ahead of an upcoming data readout, keeping an Overweight rating intact.Cantor Reinforces Conviction
• Positive Sentiment: Cantor Fitzgerald reaffirmed its Overweight rating on Gossamer Bio, signaling sustained analyst support. Read More: Benzinga Article
• Positive Sentiment: Piper Sandler also reiterated its Buy call as momentum builds around seralutinib’s development prospects.Seralutinib Momentum
• Positive Sentiment: Gossamer stock hit a new 12-month high, reflecting optimism around its clinical milestones.New 12-Month High